A new study indicates that anti-obesity drug semaglutide helps prevent cardiac events among overweight people who have cardiovascular disease, even if they also have heart failure.

The results follow a previous finding that weekly injections of semaglutide were linked to a 20% reduction in major adverse cardiac events (MACE) such as heart attacks and strokes for people with obesity or who were overweight and had cardiovascular disease.

The new study found similar cardiovascular benefits for a subgroup of study participants who were also judged to have heart failure (ie. whose hearts did not pump blood around the body properly) by a clinician at the start of the trial.

The researchers looked at data from 4,286 people out of a total of 17,605 from the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial, who were randomly assigned either semaglutide or a placebo and who were followed up over an average of more than three years.

They found that semaglutide was linked to a 28% reduction in major adverse cardiac events, as well as a 24% reduction in cardiovascular disease-related deaths for this subgroup of people with pre-existing heart failure, and a 19% reduction in deaths of any cause.

The results are released in the same week as a study that suggests a link between semaglutide and a disproportionately increased reporting of suicidality.

Benefit seen across heart failure types

Lead author Professor Deanfield (University College London Institute of Cardiovascular Science) said: “Our previous SELECT analysis showed the benefits of semaglutide for people with cardiovascular disease who had obesity or were overweight. This new study finds that, within this group, people with heart failure did just as well as people without in terms of the outcomes measured.

“This is important as there were concerns that semaglutide might be harmful for people with a type of heart failure known as reduced ejection fraction, where the heart pumps less blood around the body. Our findings show that the benefit of semaglutide was similar regardless of heart failure type.”

The study looked at data from the SELECT trial – the largest and longest clinical trial of the effects of semaglutide on weight in over 17,000 adults who did not have diabetes but who were overweight or had obesity.

Semaglutide is the active ingredient in Wegovy and Ozempic. In July, thanks to evidence from the SELECT trial, the UK medicines regulator approved Wegovy as a treatment for those with cardiovascular disease, meaning it can be prescribed privately. 

Read the full paper in The Lancet.

Diana Spencer, Senior Digital Content Editor, DDW